VRd and Dara-VRd (myeloma induction regimens)
The alphabet soup of myeloma treatment: V (bortezomib, Velcade), R (lenalidomide, Revlimid), d (dexamethasone), Dara (daratumumab), Isa (isatuximab), K (carfilzomib). Dara-VRd, a four-drug quadruplet, is now the standard first treatment for most patients.
VRd was the standard triplet for a decade (SWOG S0777). Adding a CD38 antibody made quadruplets standard: Dara-VRd before and after autologous transplant (PERSEUS) and in transplant-ineligible patients (CEPHEUS), Isa-VRd in IMROZ, with Dara-Rd (MAIA) for frailer patients. Bortezomib causes neuropathy and is often dropped after induction; lenalidomide continues as maintenance. MRD negativity rates above 60% with quadruplets are prompting trials of MRD-guided de-escalation and of CAR-T or bispecifics in place of transplant (CARTITUDE-5/6).
Pages like this
not linked directly; found by shared links- TrialCEPHEUS
Shares Bortezomib, Daratumumab, Lenalidomide, Multiple myeloma.
- PersonPaul G. Richardson
Shares Bortezomib, Lenalidomide, Multiple myeloma.
- TrialPERSEUS
Shares Bortezomib, Daratumumab, Lenalidomide, Multiple myeloma.
- PersonKenneth C. Anderson
Shares Bortezomib, Lenalidomide, Multiple myeloma.
- PairingCD38 antibody added to PI-IMiD-dex (quadruplet induction)
Shares Bortezomib, Daratumumab, Lenalidomide, Multiple myeloma.
- Key paperPERSEUS: daratumumab added to bortezomib-lenalidomide-dexamethasone around autologous transplant in newly diagnosed myeloma
Shares Bortezomib, Daratumumab, Lenalidomide, Multiple myeloma.
- TrialIMROZ
Shares Bortezomib, Lenalidomide, Multiple myeloma.
- IdeaMRD-guided treatment-free intervals in myeloma
Shares Daratumumab, Lenalidomide, Multiple myeloma.